A phase 2/3 study of bicycle toxin conjugate zelenectide pevedotin (BT8009) targeting Nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC) (Duravelo-2).

被引：0

作者：

Loriot, Yohann

Siefker-Radtke, Arlene O.

Friedlander, Terence W.

Necchi, Andrea

Wei, Alexander Z.

Sridhar, Srikala S.

Garmezy, Benjamin

Arroyo, Santiago

Gartside, Emma

Liu, Jie

Campbell, Carly

Bader, Justin

Petrylak, Daniel P.

机构：

[1] Univ Paris Saclay, Gustave Roussy Inst, Villejuif, France

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[4] Univ Vita Salute San Raffaele, IRCCS San Raffaele Hosp, Milan, Italy

[5] Columbia Univ, Med Ctr, Dept Med, New York, NY USA

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Sarah Cannon Res Inst, Nashville, TN USA

[8] Bicycle Therapeut, Cambridge, MA USA

[9] BicycleTx Ltd, Cambridge, England

[10] Yale Sch Med, New Haven, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.TPS898

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS898 / TPS898

页数：1

共 50 条

[1] A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2
Loriot, Yohann
Siefker-Radtke, Arlene O.
Friedlander, Terence W.
Necchi, Andrea
Wei, Alexander Z.
Sridhar, Srikala S.
Garmezy, Benjamin
Arroyo, Santiago
Gartside, Emma
Liu, Jie
Campbell, Carly
Bader, Justin
Petrylak, Daniel P.
Roussy, Gustave
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[2] Discovery of BT8009: A Nectin-4 Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
Mudd, Gemma E.
Scott, Heather
Chen, Liuhong
van Rietschoten, Katerine
Ivanova-Berndt, Gabriela
Dzionek, Katarzyna
Brown, Amy
Watcham, Sophie
White, Lewi
Park, Peter U.
Jeffrey, Phil
Rigby, Mike
Beswick, Paul
JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (21) : 14337 - 14347
[3] Effects of Nectin-4 targeted Bicycle Toxin Conjugate, zelenectide pevedotin (BT8009), and enfortumab vedotin on a human corneal tissue model
Kristensson, J.
Campbell, C.
Ludbrook, S.
Hirschberg, S.
Rigby, M.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S115 - S115
[4] BT8009; A Nectin-4 Targeting Bicycle Toxin Conjugate for Treatment of Solid Tumors
Rigby, Michael
Bennett, Gavin
Chen, Liuhong
Mudd, Gemma E.
Harrison, Helen
Beswick, Paul J.
Van Rietschoten, Katerine
Watcham, Sophie M.
Scott, Heather S.
Brown, Amy N.
Park, Peter U.
Campbell, Carly
Haines, Eric
Lahdenranta, Johanna
Skynner, Michael J.
Jeffrey, Phil
Keen, Nicholas
Lee, Kevin
MOLECULAR CANCER THERAPEUTICS, 2022, 21 (12) : 1747 - 1756
[5] BT8009, a Bicycle Toxin Conjugate targeting Nectin-4, shows target selectivity, and efficacy in preclinical large and small tumor models
Rigby, Michael
Bennett, Gavin
Chen, Liuhong
Mudd, Gemma
Beswick, Paul
Harrison, Helen
Watcham, Sophie
Allen, Heather
Brown, Amy
Van Rietschoten, Katerine
Jeffrey, Philip
Park, Peter U.
Haines, Eric
Keen, Nicholas
Lahdenranta, Johanna
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[6] BT8009-100: A phase I/II study of novel bicyclic peptide and MMAE conjugate BT8009 in patients (pts) with advanced malignancies associated with nectin-4 expression, including urothelial cancer (UC).
Baldini, Capucine
Goldschmidt, Vincent
Brana, Irene
Doger, Bernard
Italiano, Antoine
Cousin, Sophie
Falchook, Gerald Steven
Necchi, Andrea
Reig, Oscar
Carter, Louise
Fontana, Elisa
Verlingue, Loic
Hazard, Sebastien
Dickson, Amy
Xu, Cong
Xu, Hongmei
Sharma, Rajiv
Smethurst, Dominic
McKean, Meredith
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[7] BT8009-100 phase I/II study of novel bi-cyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies associated with nectin-4 expression
McKean, Meredith
Baldini, Capucine
Verlingue, Loic
Doger, Bernard
Falchook, Gerald
Italiano, Antoine
Lostes, Julia
Reig, Oscar
Watson, Roshawn
Hazard, Sebastien
Smethurst, Dominic
Fulci, Giulia
Xu, Hongmei
Jeffery, Phil
Lee, Kevin
Brana, Irene
Cousin, Sophie
Fontana, Elisa
Arkenau, Hendrik-Tobias
CANCER RESEARCH, 2022, 82 (12)
[8] BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced malignancies
Mckean, M.
Bendell, J. C.
Petrylak, D. P.
Powles, T. B.
Sonpavde, G. P.
Dickson, A.
Dosunmu, L.
Hennessy, M. G.
Jeffrey, P.
Rigby, M.
West, T.
ANNALS OF ONCOLOGY, 2020, 31 : S500 - S501
[9] Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.
McKean, Meredith
Falchook, Gerald Steven
Bendell, Johanna C.
Bashir, Babar
Palmisiano, Neil
Watson, Roshawn
McKenna, Mary-Anne
Campbell, Carly
Smethurst, Dominic Paul
Jeffrey, Phil
Kirui, Julius
Arkenau, Hendrik-Tobias
Fontana, Elisa
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] A phase 1 study of LY4101174 (ETx-22), an antibody-drug conjugate targeting nectin-4, in patients with advanced or metastatic urothelial cancer and other solid tumors (trial in progress)
Rosenberg, Jonathan
Sabatier, Renaud
Viceneux, Armelle
Rouge, Thibault De la Motte
Champiat, Stephane
Lebellec, Loic
Barthelemy, Philippe
Sonpavde, Guru
Gao, Xin
Niglio, Scot
Zhang, Tian
Gedye, Craig
Galsky, Matthew
Milowsky, Matthew
Reimers, Melissa
Weickhardt, Andrew
Grande, Enrique
Castellano, Daniel E.
Bilen, Mehmet
Patnaik, Amita
Zerbib, Robert
Balbas, Minna
Xu, Xiaojian
Aptaker, Kaitlyn
Balar, Arjun V.
Awada, Ahmad H.
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →